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Cerebral aneurysms (CAs) occur in 3% to 5% of the gen-eral population and are characterized by localized struc-
tural deterioration of the arterial wall, with loss of the internal 
elastic lamina and disruption of the media.1 The most dreaded 
complication of CAs is rupture, the likelihood of which is 
related to several modifiable and nonmodifiable risk factors. 
Despite advances in surgical techniques and perioperative 
management, the mortality and morbidity associated with 
aneurysm rupture remain high.2 Current therapeutic options 
are limited to invasive therapies, namely microsurgical clip-
ping and endovascular treatment, both of which carry a non-
negligible risk of procedural morbidity.
In recent years, it has become obvious that CAs are not pas-
sively enlarging vascular structures but exhibit prominent fea-
tures of inflammation and tissue degeneration. Other factors 
mainly hemodynamic, genetic, hormonal, and environmental 
may also play an important role. Knowledge of the pathogenic 
pathways of CAs may pave the way for the development of 
noninvasive therapies. The purpose of this review is to sum-
marize the most relevant data on the molecular mechanisms, 
genetics, and risk factors for aneurysm formation, growth, and 
rupture. Although there are different forms of CAs, the present 
discussion focuses on saccular aneurysms, which represent 
the most common type of CAs and are also the most common 
cause of subarachnoid hemorrhage (SAH).
Cerebral Aneurysms: an Inflammatory Disease
Increasing evidence points to inflammation as the leading fac-
tor in the pathogenesis of CAs. The inflammatory process is 
initiated by a hemodynamic insult and leads to matrix metallo-
proteinases (MMPs)–mediated degradation of the extracellular 
matrix and apoptosis of smooth muscle cells (SMCs), which 
are the predominant matrix-synthesizing cells of the vascular 
wall. These processes act in concert to weaken the arterial wall 
progressively, resulting in dilatation, aneurysm formation, and 
ultimately rupture (Figure; Table 1). The data supporting a 
major role for inflammation in CA pathogenesis are strong and 
derive from both experimental and human studies. The 2 main 
constituents of the inflammatory response and the associated 
degenerative response are macrophages and SMCs.
Macrophages are invariably noted in human aneurysm sam-
ples.3 The tissue-infiltrating macrophages not only release pro-
inflammatory cytokines that lead to recruitment of additional 
inflammatory cells, but also release MMPs that digest arterial 
wall extracellular matrix and cause further damage via upreg-
ulation of other proteinases. As such, Aoki et al4 elegantly 
demonstrated that the expression of macrophages and macro-
phage-derived MMPs was closely associated with aneurysm 
growth, and that selective inhibition of these MMPs blocked 
aneurysm progression. Likewise, macrophage-depleted mice 
were found by Kanematsu et al5 to have a substantially lower 
risk of developing CAs. Along similar lines, the inhibition of 
monocyte chemoattractant protein-1 (MCP-1), a chemokine 
regulating the migration and infiltration of macrophages, 
halted CA formation in mice.6 In a comparative study of rup-
tured and unruptured human CAs, macrophage infiltration 
was strongly associated with aneurysm rupture.7 Interestingly, 
macrophages seem to be present in human CAs in 2 different 
forms that exert opposite effects on inflammation.8 Whereas 
the proinflammatory M1 cells and the anti-inflammatory M2 
cells are present in equal proportion in unruptured aneurysms, 
the balance shifts toward M1 cells in ruptured aneurysms, 
suggesting a role for M1/M2 imbalance in the progression of 
human CAs to rupture.8 Also, the critical role of macrophages 
in CAs has allowed the development of targeted molecular 
imaging for identifying rupture-prone aneurysms,9,10 and this 
will be discussed in further detail below. Therapies targeting 
macrophage activation and MMP release in aneurysm walls or 
preventing the M1/M2 imbalance may potentially halt aneu-
rysm formation and rupture.
SMCs play a pivotal role in the formation, progression, and 
rupture of CAs. As discussed above, SMCs, mostly concen-
trated in the media, are the predominant matrix-synthesizing 
cells of the vascular wall. The media provide structural integ-
rity to the arterial wall, and the thinning of this layer contrib-
utes to aneurysm formation and rupture. Early in aneurysm 
formation, SMCs migrate into the intima in response to endo-
thelial injury and proliferate, producing myointimal hyperpla-
sia.11 Subsequently, SMCs undergo phenotypic modulation 
from a differentiated phenotype concerned with contraction 
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Figure. Cerebral aneurysm (CA) formation and rupture. Aneurysm formation is initiated by hemodynamically triggered endothelial dys-
function. An inflammatory response implicating several cytokines and inflammatory mediators as well as macrophages, T cells, and mast 
cells ensues. Concurrently, smooth muscle cells (SMCs) undergo phenotypic modulation to a proinflammatory phenotype. The inflamma-
tory response in vessel wall leads to disruption of internal elastic lamina, extracellular matrix digestion, and aneurysm formation. Loss of 
mural cells and further inflammation and vessel wall degeneration ultimately lead to CA rupture. bFGF indicates basic fibroblast growth 
factor; COX2, cyclooxygenase-2; ECM, extracellular matrix; ICAM, intercellular adhesion molecule; IL, interleukin; MCP, monocyte che-
moattractant protein; MMP, matrix metalloproteinase; NK, natural killer; NO, nitric oxide; PGD, prostaglandin D; PGE, prostaglandin E; 
ROS, reactive oxygen species; TGF, transforming growth factor; TLR, toll-like receptor; TNF, tumor necrosis factor; VCAM, vascular cell 
adhesion molecule; VEGF, vascular endothelial growth factor; and VSMC, vascular smooth muscle cell.
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to a dedifferentiated phenotype, promoting inflammation and 
matrix breakdown (downregulation of contractile genes, such 
as myocardin, and upregulation of proinflammatory genes, 
such as MMPs, MCP-1, vascular cell adhesion molecule 1, 
and interleukins).12,13 Morphologically, modulated SMCs are 
no longer arranged in tightly compacted bands but dissoci-
ate from each other to be transformed into spider-like cells 
in aneurysm walls.14 The ability of these SMCs to synthesize 
collagen is severely impaired. A late event commonly seen 
in ruptured aneurysms is the loss of SMC with thinning of 
the media.3 Guo et al15 found decreased SMC density and 
a significant increase in the activity of caspases in ruptured 
aneurysms compared with control vessels, whereas Sakaki 
et al16 added that SMCs in the wall of ruptured aneurysms 
were much more degenerated/apoptotic than those in the wall 
of unruptured aneurysms. A series of in vitro and in vivo stud-
ies by the Jefferson group found that the phenotypic modula-
tion of SMCs in CAs was induced by tumor necrosis factor-α 
(TNF-α).17,18 Specifically, TNF-α inhibited the contractile 
phenotype of SMCs and induced proinflammatory/matrix-
remodeling genes, namely MCP-1, MMPs, vascular cell adhe-
sion molecule 1, and interleukin 1β (IL-1β).17 This process 
was mediated by Kruppel-like transcription factor 4, a known 
regulator of SMC differentiation. In a follow-up study, the 
same group found that phenotypic modulation of SMCs was 
reversed with a TNF-α inhibitor after aneurysm induction.18 
Collectively, these data indicate that SMCs under the influ-
ence of inflammatory mediators, particularly TNF-α, promote 
aneurysm formation, progression, and rupture.
Although best known for their role in allergy and anaphy-
laxis, mast cells seem to be involved in the pathophysiology 
of CAs mostly through the release of various proinflammatory 
cytokines. The number of mast cells is significantly increased 
during CA formation, and their degranulation induces the 
expression and activation of MMPs.19 Additionally, mast cell 
degranulation inhibitors attenuate the inflammatory reaction 
in aneurysm walls and block the progression of CAs in mice.19 
Furthermore, Hasan et al8 found that mast cells are invariably 
present in CA walls and were more prominently upregulated 
in ruptured than in unruptured human CAs, suggesting a role 
for mast cells in aneurysm rupture.
Several cytokines and inflammatory mediators are involved 
in the pathogenesis of CAs. IL-1β and TNFα are the 2 most 
studied cytokines in CAs. IL-1β is induced in the early stages 
of CA formation in mice, and its expression promotes SMC 
apoptosis and aneurysm progression.20 Additionally, IL-1β 
inhibits collagen biosynthesis both at the transcriptional and 
post-transcriptional levels, thus further contributing to the pro-
gression and weakening of CAs.21 TNF-α promotes the crucial 
SMC phenotypic modulation in aneurysm walls and directly 
activates MMPs while also reducing the expression of tissue 
inhibitor of metalloproteinase-1.22 Moreover, Jayaraman et al23 
demonstrated that TNF-α has a proapoptotic and proinflamma-
tory action in CA walls through its downstream target FAS. In a 
recent study, Starke et al24 highlighted the critical role of TNF-α 
in both aneurysm formation and rupture. Specifically, they dem-
onstrated that CA formation (through induced hypertension and 
elastase injection) occurred in 81.8% of animals receiving only 
vehicle as compared with only 25% of TNF-α knockout mice 
and 33% of those treated with TNF-α inhibitor. Furthermore, 
TNF-α knockout mice were >12× less likely to have aneurysm 
rupture as compared with those receiving vehicle only.
Chemokines are chemoattractants for leukocytes that direct 
them toward sites of tissue inflammation. Their contribution to 
CA pathogenesis is recently being investigated. Chalouhi et al25 
compared the concentrations of chemokines and other inflamma-
tory molecules in blood samples drawn from the lumen of human 
CAs of 16 patients with blood samples from the femoral arteries 
of the same patients and found higher plasma concentrations of 
Table 1. Inflammatory Pathways and Mediators Implicated in 
CA Formation and Rupture
Pathway Mediators
Endothelial dysfunction IL-1β
NF-κB
Ets-1
MCP-1
Reactive oxygen species
Nitric oxide (NO), endothelial NO synthase, 
inducible NO synthase
Angiotensin II
Phosphodiesterase-4
Prostaglandin E2
E selectin, P selectin, vascular cell adhesion 
protein 1 (VCAM1), intercellular adhesion 
molecule 1 (ICAM1)
Phenotypic modulation and 
loss of SMCs
TNF-α
KLF-4
IL-1β
P47phox
MCP-1
MMPs
Adhesion molecules
Macrophages, M1/M2 
imbalance, leukocyte 
infiltration
MCP-1
NF-κB
Ets-1
MMPs
IL-1β
TNF-α
Normal T cell expressed and secreted
Monokine induced by γ-interferon
Interferon-γ–induced protein-10
Eotaxin
IL-8
IL-17
Vascular remodeling, cell 
death
MMP and cathepsins
TNFα
IL-1β, IL-6
Toll-like receptor 4
Fas
NO
Complement
IgG, IgM
Basic fibroblast growth factor, transforming 
growth factor α and β, and vascular 
endothelial growth factor
Reactive oxygen species
IL-1β indicates interleukin 1β; KLF-4, Kruppel-like transcription factor 4; 
MCP-1, monocyte chemoattractant protein-1; MMP, matrix metalloproteinase; 
NF-κB, nuclear factor-κ B; SMC, smooth muscle cell; and TNFα, tumor 
necrosis factor-α.
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5 chemokines (MCP-1, regulated on activation, normal T cell 
expressed and secreted [RANTES], monokine-induced-by-γ-
interferon, interferon-γ-induced protein-10, and Eotaxin) and 
2 chemoattractant cytokines (interleukin 8 and interleukin 17) 
in the lumen of CAs. These findings suggest that there may be 
an active chemokine-driven recruitment of inflammatory cells 
into the aneurysm wall. The findings match well with those of 
Krischek et al26 who reported in a networked-based gene expres-
sion analysis of CA tissue that chemokines were among the most 
significant canonical pathways involved in aneurysm tissue. 
Thus, chemokines may be a central factor in the inflammatory 
reaction in aneurysm walls, and this may open new therapeutic 
perspectives in the treatment of CAs.
With regard to the role of complement in the inflammatory 
response leading aneurysm formation, Tulamo et al27 found 
the expression of membrane attack complex to be greater in 
ruptured aneurysm samples as compared with unruptured 
samples. Complement expression was also associated with 
aneurysm wall degeneration and inflammatory cell infiltra-
tion. The same group later reported that activation of com-
plement in CAs occurs primarily via the classical pathway.28 
However, an explanation of how complement activation may 
contribute to aneurysm formation remains to be determined.
Reactive oxygen species (ROS) may also have a role in 
the pathogenesis of CAs.29 Aoki et al30 showed that ROS-
producing genes were upregulated, and that ROS-eliminating 
genes were suppressed in CAs in mice, which indicated that 
overproduction of ROS occurred in aneurysm walls. Moreover, 
both a free radical scavenger (edaravone) and the deletion of 
ROS-producing gene (p47phox) effectively inhibited CA for-
mation by suppressing inflammation in aneurysmal walls. In 
a critical review of the literature on ROS, Starke et al29 found 
that oxidative stress can induce important processes leading to 
CA formation including direct endothelial injury, SMC phe-
notypic modulation and apoptosis, recruitment and invasion 
of inflammatory cells through upregulation of chemotactic 
cytokines and adhesion molecules, and MMPs activation.
Several studies have profiled gene expression in CAs, using 
microarray or polymerase chain reaction techniques, in an 
attempt to characterize the mechanisms underlying aneurysm 
formation, growth, and rupture. Although the results were 
somewhat heterogeneous across studies, alteration in expres-
sion genes related to the inflammatory and immune responses 
as well as the extracellular matrix were frequently observed in 
CAs and more so in ruptured than in unruptured aneurysms. 
Aoki et al31 compared the gene expression profile between nor-
mal cerebral arteries and experimentally induced CAs in rats 
and found upregulation of gene expression for MMPs, ROS, 
growth factors, chemokines, complement, adhesion molecules, 
and apoptosis in CAs. Kurki et al32 compared the whole-genome 
expression profile of 11 ruptured and 8 unruptured CAs using 
oligonucleotide microarrays and reported that response to tur-
bulent blood flow, chemotaxis, leukocyte migration, oxidative 
stress, vascular remodeling, and extracellular matrix degrada-
tion were significantly upregulated biological processes in rup-
tured aneurysms. Significantly enriched genes were toll-like 
receptor signaling, nuclear factor-κB, hypoxia-inducible factor-
1A, and ETS transcription factor–binding sites. Conversely, 
Pera et al33 examined transcription profiles in ruptured CAs, 
unruptured CAs, and control middle meningeal arteries and 
paradoxically found downregulation of genes involved with the 
immune system and inflammation in ruptured samples. These 
results suggested a protective role of inflammation against 
aneurysm rupture. However, the study had limitations pertain-
ing to sample size, baseline comparability, and extracerebral 
control tissue. Overall, gene expression studies provide useful 
data for understanding the pathophysiology of CAs; however, 
differences in microarray technique, statistical analysis, control 
tissue, type of aneurysm, and studied population make compari-
son across studies difficult.
Given the critical role of inflammation in aneurysm patho-
genesis, several therapeutic strategies have been investigated 
with overall mixed but promising results (Table 2).3 Perhaps 
the most promising of all strategies has been acetylic acid 
(ASA), more commonly referred to as aspirin. ASA exerts its 
antiplatelet and anti-inflammatory actions by irreversible acet-
ylation of cyclooxygenase-1 and -2, and possibly also through 
the formation of nitric oxide radicals and the modulation of 
inﬂammatory signaling pathways by the main ASA metabo-
lite, salicylic acid. In a case–control study from patients 
enrolled in the International Study of Unruptured Intracranial 
Aneurysms, Hasan et al34 found that patients using aspirin 
had a lower risk of hemorrhage than those who never used 
aspirin. Building on this work, the same group reported that 
ruptured aneurysms have higher immunohistochemical stain-
ing for cyclooxygenase-2 and microsomal prostaglandin E2 
synthase 1, thus concluding that the protective effect of aspirin 
against rupture of CAs is mediated in part by inhibition of 
cyclooxygenase-2/microsomal prostaglandin E2 synthase 1.28 
Indeed, in a trial comparing 5 patients treated with ASA and 
5 other control patients, the expression of macrophages and 
Table 2. Noninvasive Therapies for Preventing Formation, 
Growth, or Rupture of Cerebral Aneurysms
Therapies Showing Efficacy Therapies With No Effect
Aspirin (human studies)34,36 Statins (human studies)37
Nuclear factor-κB decoy ODN (rats)38 Valsartan (rats)39
Pravastatin, low dose (rats)40 Pravastatin, high dose induces 
aneurysm formation (rats)40
Simvastatin (rats)41 Simvastatin (rats)40 
Infliximab (TNF-α inhibitor; rats)24 Clodronate liposomes (deplete 
circulating monocytes; rabbits)42
MMP inhibitor (Tolylsam; rats)4
MCP-1 inhibitor (7ND; rats)6
Phosphodiesterase-4 inhibitor 
(Ibudilast; rats)43
Cathepsin inhibitor (NC-2300; rats)44
Mast cell degranulation 
inhibitor (Tranilast, emedastine 
difumarate; rats)19
Free radical scavenger 
(Edaravone; rats)30
Doxycycline (MMPs inhibitor; rabbits)42
MCP-1 indicates monocyte chemoattractant protein-1; MMP, matrix metallo-
proteinase; ODN, oligodeoxynucleotide; and TNF-α, tumor necrosis factor-α.
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inflammatory molecules in CAs after clipping was found to 
be significantly decreased in the ASA group.35 Although this 
study provided novel data that ASA may attenuate the inflam-
matory process in the walls of human CAs, larger studies with 
long follow-up periods are needed to address whether ASA 
also prevents aneurysmal SAH. Bringing confirmation to the 
work of Hasan et al34 is a recently published study from Europe 
that showed that chronic low dose aspirin therapy has a protec-
tive effect against SAH and does not increase the risk of intra-
cerebral hemorrhage.36 Furthermore, there was a particularly 
pronounced trend toward decreased risk of SAH among those 
on long-term aspirin therapy (>3 years). Collectively, these 
data suggest that aspirin may be a serious noninvasive strategy 
for prevention of SAH. If the efficacy of aspirin is confirmed 
in a randomized controlled trial, aspirin could potentially be 
offered as a treatment for those patients in whom the risk of 
invasive therapy exceeds the risk of aneurysm rupture. For 
example, a 75-year-old man with a 5-mm CA would be a per-
fect candidate for aspirin treatment. Likewise, aspirin may 
be used to decrease the risk of aneurysm rupture in patients 
refusing any sort of invasive therapies or in countries where 
invasive, specialized therapies are not available. The fact that 
aspirin is an inexpensive and widely available and used drug 
makes it an ideal candidate in this setting.
Besides ASA, statins have extensively been investigated 
as possible therapeutic agents for CAs but the data have 
been conflicting thus far. Although a lower dose of statins 
(5 mg/kg per day) reduced endothelial damage and inhib-
ited aneurysm formation in mice, higher doses (25–50 mg/kg 
per day) facilitated aneurysm growth and promoted aneurysm 
rupture.3 Further study will be needed to determine whether 
statins may have a future role in the treatment of CAs. Despite 
evidence for a potential role of angiotensin in the pathophysi-
ology of CAs, angiotensin-receptor blockers have shown little-
to-no efficacy in preventing aneurysm formation and growth.3
Hemodynamics, Endothelial Dysfunction, and CAs
Hemodynamic stress is the initiating factor for CA forma-
tion.3 This is best illustrated by the observation that CAs occur 
at arterial junctions, bifurcations, or abrupt vascular angles 
where excessive hemodynamic stresses are exerted on arte-
rial walls. In a well-designed study, Meng et al45 created new 
branch points in the carotid vasculature of 6 dogs and observed 
destructive remodeling in the adjacent region of flow accelera-
tion that resembled the initiation of an intracranial aneurysm, 
characterized by disruption of the internal elastic lamina, loss 
of medial SMCs, reduced proliferation of SMCs, and loss of 
fibronectin. They concluded that a combination of high wall 
shear stress (WSS) and a high gradient in WSS strongly pre-
disposes to CA formation. The same group extended their 
previous findings by demonstrating a correlation between the 
degree of destructive remodeling accounting for internal elas-
tic lamina loss, medial thinning, and luminal bulging with the 
magnitude of WSS at arterial bifurcations.46 
Although it is clear that high WSS drives CA formation, 
the question of whether low or high WSS promotes aneurysm 
progression and rupture remains unanswered. Whereas Cebral 
et al47 found that high and concentrated WSS was associated 
with aneurysm rupture, several computational fluid dynamic 
studies have shown that the WSS at the tip or bleb of an aneu-
rysm, where rupture most commonly occurs, is in fact low.48,49 
It is thought that low WSS may induce apoptosis of endothe-
lial cells, thus promoting the structural remodeling/fragility 
of the aneurysm wall and ultimately leading to CA rupture. 
In an attempt to reconcile the conflicting data, some authors 
have proposed that low WSS may trigger the growth and rup-
ture of large, atherosclerotic aneurysm phenotypes through 
an inflammatory reaction, whereas high WSS may trigger the 
growth and rupture of small or bleb aneurysm phenotypes 
though a mural response (MMP production, mural cell apop-
tosis, medial thinning).50 However, the proposed mechanisms 
remain purely speculative, and further investigation is needed 
to answer this crucial question.
Endothelial dysfunction is a hallmark of CA biology. As 
discussed above, endothelial dysfunction and vessel wall 
inflammation and remodeling are directly triggered by WSS. 
Kadirvel et al51 elegantly revealed endothelial cell loss and dif-
ferential expression of biological markers of vascular remod-
eling namely MMPs in areas of low WSS in elastase-induced 
saccular aneurysms. Likewise, Wang et al52 showed that WSS 
induces endothelial dysfunction, as evidenced by the loss 
endothelial nitric oxide synthase expression, and upregulation 
of inflammatory markers in a canine model of CAs. Jamous 
et al31 reported that endothelial cell injury induced by hemo-
dynamic abnormalities was the earliest change in aneurysm 
wall, followed by the formation of an inflammatory zone that 
leads to proteolytic destruction of the vascular extracellular 
matrix by MMP. Some investigators also suggest that the acti-
vation of nuclear factor-κ B in endothelial cells pursuant to 
hemodynamic stress may be the earliest step in CA formation 
because dramatic blockade of aneurysm formation was seen 
after inhibition of nuclear factor-κ B in mice.38 As discussed 
above, the expression of MCP-1 by endothelial cells is pivotal 
in recruiting macrophages and other leukocytes into the aneu-
rysm wall. Along these lines, endothelial tight junctions were 
found to be disrupted in CAs and were associated with the 
migration of leukocytes through endothelial gaps into aneu-
rysm walls.53 Collectively, these data indicate that endothelial 
dysfunction, driven by hemodynamic stress, is an early event 
in CA physiopathology that initiates and nurtures the inflam-
matory reaction in arterial walls.
Genetics of CAs
Despite extensive research, relatively little is known about the 
genetics of CAs. The role of genetics in CAs may be high-
lighted by the increased risk of aneurysms and SAH in first-
degree relatives of patients with SAH. As such, CAs are noted 
in 2.3% of the general population versus 4% of those with 1 
affected first-degree relative and 8% of those with 2 affected 
first-degree relatives.54 Some heritable diseases of the connec-
tive tissue and extracellular matrix are also associated with an 
increased risk of CAs and SAH. Autosomal dominant polycys-
tic kidney disease is the most common heritable disease associ-
ated with SAH. CAs may occur in 10% to 13% of patients with 
autosomal dominant polycystic kidney disease and in ≤23% of 
those >60 years old, but routine screening is not recommended 
 at Thomas Jefferson Universi on June 17, 2014http://stroke.ahajournals.org/Downloaded from 
3618  Stroke  December 2013
in this population.54 Ehlers-Danlos type IV (caused by muta-
tion of collagen type III), fibromuscular dysplasia, and pos-
sibly Marfan syndrome (mutation of ﬁbrillin-1 gene) are also 
heritable disorders associated with CAs and SAH.54
Whether genetics contribute to CA formation and rupture 
is not certain. The largest twin cohort to date, the population-
based Nordic Twin Cohort, which followed 79 644 com-
plete twin pairs of Danish, Finnish, and Swedish origin for 
6.01 million person-years did not find a significant degree of 
genetic contribution to SAH.55 Based on these data, it might 
be tempting to conclude that aneurysmal SAH has little-to-no 
genetic basis, and that modifiable risk factors are the major 
determinants of SAH risk. In this case, familial CAs would be 
attributable to the familial clustering of modifiable risk fac-
tors. On the contrary, the powerful genome-wide linkage stud-
ies have identiﬁed several genetic loci for CAs, namely 7q11, 
14q22, 5q22-31 in a Japanese study and 19q13.3 in a Finnish 
study.56 Although no specific gene has been shown thus far to 
be associated with CAs, these genetic loci include some prom-
ising candidate genes coding for extracellular matrix proteins 
such as elastin and collagen. Other candidate genes that have 
been studied are those associated with vascular wall forma-
tion, matrix degradation, and response of the cerebral artery 
to increased stress (including inflammation).56 Among those 
genes are lysyl oxidase, fibrillin 2, α1 antitrypsin, MMPs, 
tissue inhibitor of metalloproteinase-1, endoglin, angioten-
sin-converting enzyme, nicotinamide adenine dinucleotide 
phosphate-oxidase, p22phox, phospholipase C, endothelial 
nitric oxide synthase, transforming growth factor-β receptors, 
and polycystin.56 It should be noted that none of the findings of 
genetic association studies have been consistently reproduc-
ible, and this may be related to the fact that these studies dealt 
with different populations and were probably underpowered 
to detect a significant genetic association. Large multicenter 
studies will be needed to more clearly elucidate the genetic 
platform of CAs; however, it is likely that both genetic factors 
as well as environmental factors play a role in CA pathogen-
esis, complicating efforts at disease gene identification.
In clinical practice, genetic approaches may have applica-
tion in identifying aneurysm-prone patients and rupture-prone 
aneurysms or even in controlling aneurysm development and 
rupture. Gene therapy, a technique that consists of inserting 
a functioning gene into a cell to correct a genetic error or to 
introduce a new function may be a potential therapeutic strat-
egy for CAs.57 For example, gene therapy for inhibiting the 
overexpression of MMPs, the activation of macrophages, or 
the phenotypic modulation of SMCs may theoretically have 
efficacy in preventing aneurysm rupture. Unfortunately, how-
ever, gene therapies have the best chance of success only if a 
specific defective gene is identified, as in cystic fibrosis, for 
example. Promoting healing after coil embolization is another 
application of gene therapy, and coils carrying antibody-teth-
ered adenovirus may enhance direct gene transfer.57 Candidate 
genes are those involved in vascular remodeling and include 
growth factors, metalloproteinase inhibitors, and MCP-1.57,58
Common Risk Factors for CAs
There are several risk factors for CAs. A recent, large meta-
analysis that included 1450 unruptured CAs in 94 912 patients 
from 21 countries identified autosomal dominant polycys-
tic kidney disease, a positive family history of CA or SAH, 
female sex, and older age as significant risk factors for harbor-
ing CAs.59 The meta-analysis did not find a higher prevalence 
of CAs in Finnish and Japanese populations, which suggests 
that the higher incidence of SAH in those countries60 is related 
to higher risks of aneurysm rupture. Smoking and hyperten-
sion are 2 well-established risk factors for CAs that were not 
included in this meta-analysis.54 However, the same group later 
reported in a well-designed case–control study (206 patients 
with CAs and 574 controls) that active smoking (odds ratio, 
3.0) and hypertension (odds ratio, 2.9) were strong risk factors 
for CAs and had an important additive effect (odds ratio, 8.3).61 
It is important to note that cigarette smoking may particularly 
increase the susceptibility for CA formation in patients with 
certain gene variants namely on chromosomes 8q and 9p.62 
A recent case–control study found a 10-fold increase in the 
prevalence of CAs in patients with bicuspid aortic valve (10% 
versus 1.1%).63 An abnormality of cells derived from the neural 
crest could explain the association of bicuspid aortic valve with 
CAs because the aortic valvular cusps and the media of the 
aortic arch and its branches including cervicocephalic arter-
ies are all composed of cells of neural crest origin.63 Patients 
with Ehlers-Danlos syndrome type IV, a rare disease caused by 
abnormal synthesis of collagen type III, have a structural vas-
cular fragility predisposing to CA formation as well as arterial 
dissection and carotid-cavernous fistulas.64 Concerning ethnic-
ity, the risk of harboring an aneurysm seems to be equivalent in 
whites, blacks, and Hispanics.65 Finally, regular physical exer-
cise may decrease the risk of harboring an aneurysm.61 
It is well known that women are at higher risk of aneurysm 
formation, but the female preponderance becomes evident 
only in the perimenopausal and postmenopausal periods.60 
Indeed, an earlier age at menopause is associated with the 
presence of a CA, and hormone replacement therapy protects 
against SAH.66,67 Additionally, animal studies have shown a 
significant protective role of estrogen against the formation 
and progression of CAs.68 The protective role of estrogen is 
likely related to its beneficial effects on the inflammatory 
reaction in cerebral vessels and the function of endothelial 
cells. These effects may involve the inhibition of nuclear 
factor-κ B and IL-1β–mediated expression of adhesion mol-
ecules, with reduction of adhesion of leukocytes into cerebral 
endothelium. Thus, estrogen is undoubtedly one of the numer-
ous therapeutic strategies that may potentially prove efficient 
in SAH prevention.
Currently, it is recommended to screen for CAs in patients 
with a positive family history. Experts recommend screening 
all individuals with 2 affected first-degree relatives because 
of the high frequency of CAs in this group.54,69 It may also 
be reasonable to screen patients who have 1 affected first-
degree relative if they possess other risk factors for harboring 
CAs such as (1) female sex, (2) older age, (3) active smoking, 
(4) hypertension, (5) sibling of the affected relative, and (6) 
affected relative harbors multiple aneurysms at a young age.
Common Risk Factors for SAH
The annual rupture rate for CAs is 0.95%, as identified by 
the recent well-designed Japanese cohort.70 The same study 
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also found that larger aneurysms, aneurysms arising from the 
posterior and anterior communicating arteries, and aneurysms 
with a daughter sac have higher rates of rupture. Specifically, 
the annual rupture rate by location was 0.26% for paraclinoid, 
0.67% for middle cerebral artery, 1.31% for anterior commu-
nicating, 1.72% for posterior communicating, and 1.90% for 
basilar artery aneurysms.70 The annual rupture rate by size was 
0.36% for 3 to 4 mm, 0.50% for 5 to 6 mm, 1.67% for 7 to 
9 mm, 4.37% for 10 to 24 mm, and 33.4% for giant aneurysms 
(≥25 mm). A similar association between size and risk of rup-
ture was observed in the International Study of Unruptured 
Intracranial Aneurysms.71 The threshold for treating aneu-
rysms arising from anterior/posterior communicating arter-
ies and the posterior circulation should be lower than that for 
other locations. In our experience, most ruptured aneurysms at 
those locations tend to be small lesions (≤7 mm).
Besides aneurysm size and location, cigarette smoking is a 
strong risk factor for SAH that has been consistently reported 
in several studies.72,73 Juvela et al74 recently reported the results 
of long-term follow-up (median, 21 years) of 142 patients 
with 181 unruptured CAs and found that cigarette smoking in 
addition to anterior communicating artery location, decreas-
ing patient age, and aneurysm size ≥7 mm independently pre-
dicted aneurysm rupture. Interestingly, a case–control study 
reported that smoking may interact with a positive family his-
tory of SAH to increase the risk of SAH further than their indi-
vidual risks.75 Cigarette smoke may lead to CA formation and 
rupture through a variety of mechanisms that were recently 
reviewed by Chalouhi et al.72 Most of these mechanisms are 
related to inflammation. On closer inspection, smoking may 
cause hemodynamic stress on arterial walls, induce endothe-
lial dysfunction/apoptosis, promote SMC phenotypic modu-
lation through Kruppel-like transcription factor 4, increase 
inflammatory cell infiltration and cytokine release, and most 
importantly generate ROS.72 In other terms, cigarette smoke 
may affect every step in the cascade of events leading to aneu-
rysm formation, growth, and rupture. Patients harboring CAs 
should be strongly counseled to quit smoking especially when 
observation is elected. The importance of this simple interven-
tion cannot be overemphasized. Even in those who undergo 
embolization, cigarette smoking is a risk factor for aneurysm 
recurrence, and patients should also be urged to quit smok-
ing.76 In addition to smoking, hypertension was found to pre-
dispose to SAH in prospective population-based follow-up 
cohorts.73 Therefore, blood pressure control is another simple 
intervention that may help decrease the risk of aneurysm rup-
ture. For some investigators, however, hypertension is a risk 
factor for CA formation but does not affect the risk of rupture 
once the aneurysm has been formed. 
Although heavy alcohol consumption has been shown to 
increase the risk of SAH, it does not predispose to aneurysm 
formation and growth.54 The increased risk of SAH with alco-
hol use is likely the result of transient increases in blood pres-
sure. Data from case–control studies suggest that frequent 
intake of fat increases the risk of SAH while frequent use of 
skim or reduced-fat milk and fruit as well as dietary antioxi-
dants and soy products is protective against SAH.72 Further 
studies are needed to confirm these observations. Finally, Vlak 
et al77 identified coffee consumption and cola consumption in 
addition to anger, startling, straining for defecation, sexual 
intercourse, nose blowing, and vigorous physical exercise as 
trigger factors for aneurysmal SAH.
Overall, aneurysms ≥7 mm in diameter should be treated 
because of their propensity to rupture, except in older patients 
and those with significant medical comorbidities and short 
life expectancy. Factors that warrant strong consideration for 
treatment regardless of the size of the aneurysm include young 
patient age, change in the size or configuration of the aneu-
rysm, and the presence of multiple, daughter sac, or symp-
tomatic aneurysms. Factors that may favor intervention over 
observation are active smoking, hypertension, posterior cir-
culation aneurysm, anterior/posterior anterior communicating 
artery aneurysms, previous SAH, history of familial SAH, and 
high aspect ratio.
Aneurysm Geometry and Risk of Rupture
A multitude of geometric indices of CAs have been studied as 
possible determinants of rupture risk. Although sophisticated 
mathematical models accounting for the 3-dimensional shape 
of the aneurysm have been used, only simple indices that can 
be calculated in the office setting are most useful in clinical 
practice. The aspect ratio defined as CA height divided by 
neck diameter is the most studied and perhaps the most useful 
shape parameter. In their initial work on aspect ratio, Ujiie 
et al78 reported that 80% of ruptured aneurysms had an aspect 
ratio of >1.6, whereas 90% of unruptured aneurysms had an 
aspect ratio of <1.6. An optimal aspect ratio threshold value, 
however, above which CAs may be deemed as dangerous 
remains to be determined because different researchers have 
reported different thresholds for the aspect ratio. The rationale 
behind the aspect ratio is that blood flow is sluggish, and WSS 
is low in aneurysms with a high aspect ratio (ie, a large fundus 
and a small neck), which as discussed above promotes aneu-
rysm wall remodeling and fragilization. In the clinical setting, 
although aspect ratio cannot be relied on as a sole predictor of 
aneurysm rupture, an aspect ratio >1.6 should favor interven-
tion over observation in borderline cases.
Another simple and useful geometric index, particularly 
suitable for small aneurysms, is the aneurysm-to-vessel size 
ratio more commonly referred to as size ratio. In a recent large 
study by Kashiwazaki et al79 that included 854 ruptured and 
180 unruptured CAs, size ratio strongly correlated with aneu-
rysm rupture and was found to be the only predictive factor for 
small CAs rupture. In clinical practice, this means that a 3-mm 
aneurysm arising from the anterior communication artery has 
a higher risk of rupture than a 3-mm aneurysm of the paracli-
noid internal carotid artery.
Hoh et al80 analyzed 30 patients with multiple CAs where 
each patient harbored 1 ruptured lesion and ≥1 unruptured 
lesions. The authors found that aneurysms with high bottle-
neck factor were more likely to rupture as were those with a 
high height-width ratio (ie, long and thin). Other indices not 
covered in this review have also been proposed and showed 
some correlation with aneurysm rupture. Overall, because 
unruptured aneurysms are being detected with increasing fre-
quency, simple and reliable measurements and indices such 
aspect ratio, size ratio, and bottleneck factor may be valuable 
to formulate an optimal treatment plan for a given patient.
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Growth of CAs
The growth of a CA is a strong risk factor for future rupture. 
As such, many clinicians recommend treating any aneurysm 
that has increased in size during the follow-up period. The 
approach is justified because the same factors that drive aneu-
rysm growth, namely inflammation and matrix degeneration, 
eventually lead to its rupture. This hypothesis is also sup-
ported by findings from prospective cohorts. In a recent large 
study that followed 258 unruptured aneurysms with computed 
tomography angiography, the annual risk of rupture was 
found to be 2.4% in aneurysms with growth versus only 0.2% 
in those without growth (ie, 12-fold increase in risk of rup-
ture).81 The risk of aneurysm growth itself was associated with 
tobacco smoking and initial size. The authors concluded that 
aneurysm growth was not uncommon, and that all incidental 
aneurysms require longitudinal follow-up imaging to monitor 
for possible growth, including small lesions.81 
An aneurysm grows either by expansion of the wall because 
of proliferation of mural cells with production of extracellular 
matrix and myointimal hyperplasia, or by distension attribut-
able to hemodynamic pressure in degenerated CAs, or most 
commonly by a combination of these 2 mechanisms.82 The 
inflammatory reaction is a major factor in this process because 
it drives both mural cell growth with extracellular matrix 
production and degeneration of the aneurysm wall. Indeed, 
inhibition of nuclear factor-κ B, ROS, MMPs/cathepsin, and 
MCP-1 was shown to decrease aneurysm growth.3 Mitogen-
activated protein kinases, a family of intracellular signaling 
proteins that have a critical role in cell growth, prolifera-
tion, differentiation, and apoptosis, have also been shown to 
be actively involved in aneurysm growth. Specifically, the 
proapoptotic p54 Jun N-terminal kinase and the proinflam-
matory p38 seem to be closely associated with CA growth, 
although the involved pathways remain poorly understood.83 
Overall, the mechanisms underlying CA growth seem to be 
complex. Although, most CAs will grow before rupturing, 
many aneurysms will not. This may suggest that the pro-
cesses driving aneurysm progression and rupture may not be 
entirely identical. 
In patients managed conservatively, periodic follow-up 
(every 6–12 months) with noninvasive imaging studies (mag-
netic resonance angiography or computed tomography angi-
ography) is recommended. Strong consideration for treatment 
should be given to any aneurysm that grows over the follow-
up period because this suggests active inflammatory processes 
in the aneurysm wall.
Targeted Imaging of Inflammation: the Emerging 
Role of Ferumoxytol-Enhanced MRI
Targeted imaging of inflammatory cells and molecules 
involved in CA pathogenesis is an interesting strategy that 
may provide important information on the natural history of 
these lesions. Ferumoxytol-enhanced MRI is one such tech-
nique that is recently being investigated. Ferumoxytol is a 
member of the class of nanoparticles known as ultrasmall 
superparamagnetic iron oxide and is approved by the Food 
and Drug Administration as a treatment for iron deficiency 
anemia in patients with chronic renal failure. It also is useful 
as an intravascular contrast agent and an inflammatory marker 
when imaging is delayed because it is cleared by macrophages 
(usually within 24–72 hours). Hasan et al9,35,84 have investi-
gated the possibility of using ferumoxytol-enhanced MRI for 
noninvasive assessment of the inflammatory status of CAs 
through the detection of the activity of macrophages. In their 
initial work, they found that the optimal technique for imag-
ing macrophages in human CA walls is infusion of 5 mg/kg of 
ferumoxytol and imaging at 72 hours after injection.10 Later, 
they demonstrated that the findings of ferumoxytol-enhanced 
MRI may well predict the risk of aneurysm rupture.9 Combing 
radiological and histological findings, they found that CAs 
with early uptake of ferumoxytol (at 24 hours) exhibited more 
intense inflammation in their walls and had a higher risk of 
rupture than aneurysms with no or only late uptake of feru-
moxytol (at 72 hours).9 Thus, if validated in larger studies, 
the technique may allow physicians to differentiate unstable 
aneurysms that require intervention from stable aneurysms 
where observation is appropriate. Specifically, this technique 
could prove particularly useful in identifying rupture-prone 
aneurysms in patients that often pose a therapeutic dilemma, 
namely elderly patients (>70 years old) and patients harbor-
ing small aneurysms (<5–7 mm). Moreover, ferumoxytol-
enhanced MRI may allow noninvasive monitoring of the effects 
of anti-inflammatory pharmacological interventions (such as 
ASA) on CAs.35,84 As discussed above, if aspirin is adopted 
as a therapy for CAs, the technique may be used to identify 
those who respond to medical treatment versus those who will 
require more invasive treatment. Future improvements in tech-
nique and MRI signal quantification may allow efficient use of 
ferumoxytol-enhanced MRI in clinical practice.
Conclusions
Inflammation plays a central role in the pathogenesis of CAs. 
The common pathway for CA formation, growth, and rupture 
includes initially an endothelial dysfunction induced by hemo-
dynamic stress, followed by an inflammatory reaction in arterial 
walls involving primarily macrophages and SMCs, and finally a 
degradation of the extracellular matrix by MMPs, which paves 
the way for aneurysm rupture. Knowledge of these mechanisms 
has allowed the conception of promising molecular-based imag-
ing studies identifying rupture-prone CAs. Pharmacological 
therapy targeting the inflammatory reaction is also being 
investigated as a potential therapeutic strategy for CAs. Future 
experimental studies and clinical trials will be needed to further 
deepen our knowledge of this complex disease and to provide 
patients with efficient and innocuous therapies.
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